3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase NA
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other neoplasm
2
Other hematologic neoplasm
2
Myeloid
2
Lymphoid
2
Breast
2
Head & Neck
1
Gastrointestinal
1
Conditions
Breast Neoplasms
2
Interventions
Trastuzumab
349
Paclitaxel
310
Cyclophosphamide
286
Docetaxel
267
Carboplatin
215
Capecitabine
215
Letrozole
185
Fulvestrant
178
Doxorubicin
166
Bevacizumab
136
Anastrozole
120
Tamoxifen
117
pertuzumab
114
pembrolizumab
113
Epirubicin
110
exemestane
107
Vinorelbine
106
Gemcitabine
106
Albumin-Bound Paclitaxel
92
Lapatinib
84
130-nm albumin-bound paclitaxel
83
Radiotherapy
79
palbociclib
75
eribulin
73
Cisplatin
69
pyrotinib
66
Taxes
65
Everolimus
55
Goserelin
50
Drug Therapy
50
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Patient Reported Outcome Measures
×
Breast
×
Clear all
NCT04272801
2025-10-22
POWER
University of Virginia
Phase 2
Active not recruiting
84 enrolled
9 charts
NCT05932667
2023-12-21
DEMETER
Institut Curie
Phase 2
Terminated
1 enrolled